The clinical problem the team set out to address is deceptively simple to state and notoriously hard to quantify. Diabetic neuropathy damages peripheral nerves through chronic exposure to high blood glucose, producing symptoms that range from burning pain and tingling in the feet to numbness, muscle weakness, and loss of balance. Because the damage is often insidious, patients may adapt their lives around it, walking less, sleeping poorly, withdrawing from social activity, and quietly losing vitality. Generic quality-of-life instruments can miss these specific burdens, while existing neuropathy-specific scales are lengthy, linguistically awkward, or validated only in Western populations. In Indonesia, where diabetes prevalence continues to climb and health systems face resource constraints, the absence of a validated, locally appropriate instrument has left clinicians and researchers without a practical yardstick.

The DN-SF11 was constructed in two deliberate stages. First, the authors conducted a structured literature review to identify the domains of life most consistently disrupted by diabetic neuropathy, then distilled them into eleven items spanning five dimensions: Pain, Physical Function, Therapy Impact, Vitality, and Mental Health. The choice of domains reflects a biopsychosocial model of the disease, in which nerve damage initiates a cascade that runs from physical symptoms through functional limitation to emotional consequences. Second, the draft items were scrutinized by experts using the Delphi method, an iterative consensus technique in which panelists rate and re-rate each item across successive rounds until agreement stabilizes. Each item was then scored with the Content Validity Index, a metric expressing the proportion of experts who judge an item relevant and clear, ensuring that every question earned its place on the form.

With the instrument drafted, the team moved to statistical validation in a pilot sample of 40 patients with diabetic neuropathy. Forty participants is a small cohort by the standards of psychometric research, and the authors are explicit that this is a preliminary study, but the sample size is defensible for exploratory work when paired with the right analytical machinery. That machinery was Partial Least Squares Structural Equation Modelling, or PLS-SEM, a variance-based approach that estimates relationships between latent constructs, the unobservable qualities such as pain or vitality that questionnaires attempt to measure through multiple indicators. Unlike covariance-based SEM, which typically requires several hundred respondents to estimate models reliably, PLS-SEM is designed for exactly the kind of small-sample, theory-building exercise this pilot represents.

The internal consistency results were the study’s clearest headline. Cronbach’s alpha, the standard statistic for how coherently a set of items measures a single construct, came out at 0.883 for the full instrument, comfortably above the conventional 0.70 threshold and approaching the 0.90 level often cited as excellent. In practical terms, this means the eleven items behave as if they are all probing the same underlying phenomenon of neuropathy-related quality of life, rather than measuring eleven loosely related things. For an instrument intended to be short enough for routine clinical use, achieving this level of coherence with so few items is the central technical achievement of the study.

Convergent and discriminant validity, the twin pillars of construct validation, also performed satisfactorily. Convergent validity asks whether items intended to measure the same dimension actually correlate strongly with one another, typically assessed through indicator loadings and average variance extracted. Discriminant validity asks the opposite question: whether dimensions that are conceptually distinct, such as Pain and Mental Health, can be statistically told apart rather than collapsing into one undifferentiated blob of distress. The DN-SF11 passed both tests, suggesting its five-dimension architecture is not merely a theoretical convenience but a structure that emerges from patients’ own responses. This matters because dimension-level scores are only meaningful if the dimensions genuinely differ.

Perhaps the most scientifically interesting findings came from the structural model, which maps hypothesized causal pathways among the dimensions. The analysis indicated that Physical Function and Therapy Impact both exert positive influences on Vitality, and that Vitality in turn significantly predicts Mental Health outcomes. Read as a pathway, the model suggests that how well patients can move and function, and how they experience the effects of their treatment, feed into their sense of energy and liveliness, which then shapes their psychological state. This chain, from body to spirit, echoes a well-established literature on the downstream mental health burden of chronic physical illness, but seeing it reproduced in an Indonesian neuropathy cohort with a purpose-built instrument gives the pathway local empirical grounding.

The therapeutic dimension deserves particular attention because it is often neglected in quality-of-life instruments. Patients with diabetic neuropathy are typically managed with analgesics, anticonvulsants, antidepressants repurposed for nerve pain, and strict glycemic control, and the side effects and daily burdens of these regimens can themselves degrade wellbeing. By including Therapy Impact as an explicit dimension, the DN-SF11 acknowledges that treatment is not a neutral backdrop but an active ingredient in the patient’s experienced quality of life. For clinical pharmacists, who are increasingly embedded in Indonesian diabetes care teams, a score that captures this dimension could flag patients whose regimens are technically effective yet subjectively corrosive.

The study’s limitations are acknowledged by its authors and are worth stating plainly. Forty participants cannot establish the stability of the instrument over time, since test-retest reliability requires repeated administration in a larger sample. Criterion validity against established gold-standard instruments, responsiveness to clinical change, and cross-regional generalizability across Indonesia’s linguistically and culturally diverse provinces all remain to be demonstrated. The authors themselves recommend further large-scale validation studies, and the PLS-SEM framework, while appropriate for exploration, produces estimates that should be treated as provisional until confirmed in bigger cohorts with more conservative modeling. The ethics approval from RSUD dr. H. Jusuf SK in North Kalimantan, conducted under the Declaration of Helsinki with written informed consent from all participants, does however establish a sound procedural foundation for that follow-up work.

Even so, the significance of a validated eleven-item scale should not be underestimated. Long questionnaires impose a real cost in busy outpatient clinics, and respondent fatigue degrades data quality in exactly the populations, elderly, painful, fatigued, where measurement matters most. A short form that preserves psychometric integrity opens the door to routine quality-of-life monitoring in Indonesian diabetes care, to locally grounded clinical trials of neuropathy therapies, and to health-economic analyses that can finally quantify the societal burden of diabetic nerve damage in the country. If subsequent large-scale validation confirms what this pilot suggests, the DN-SF11 could become a small questionnaire with an outsized role in how Indonesia measures, and ultimately improves, the lives of millions of patients living with diabetic neuropathy.

Subject of Research: Development and preliminary validation of a short quality-of-life questionnaire for diabetic neuropathy patients in Indonesia

Article Title: A pilot study on the development and preliminary validation of the diabetic neuropathy short form 11 to assess quality of life in Indonesia

Article References: Syuhada, S., Anggadiredja, K., Kurniati, N. F., & Akrom, A. (2026). A pilot study on the development and preliminary validation of the diabetic neuropathy short form 11 to assess quality of life in Indonesia. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00438-y

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00438-y

Keywords: diabetic neuropathy, quality of life, questionnaire validation, DN-SF11, PLS-SEM, Cronbach's alpha, Indonesia, psychometrics, mental health, chronic pain, Delphi method, pilot study

The lateral femoral cutaneous nerve is unusual among the nerves of the leg because it carries only sensory fibers, not motor ones. It typically originates from the second and third lumbar spinal levels, travels down through the pelvis, and passes under or through the inguinal ligament near the front of the hip, just medial to a bony landmark called the anterior superior iliac spine. Once past the ligament, it splits into anterior and posterior branches that supply sensation to the front-outer and outer thigh, respectively. Because the nerve carries no motor fibers, meralgia paresthetica produces pain, burning, tingling, and numbness without any weakness or reflex changes, a hallmark that helps clinicians distinguish it from other causes of leg pain.

Why the nerve gets squeezed varies from person to person. Physical causes include tight clothing, pregnancy, obesity, and, rarely, tumors. Metabolic and chemical factors can also play a role, with diabetes mellitus, alcohol use disorder, hypothyroidism, and lead poisoning all implicated in nerve dysfunction. In some cases the damage is iatrogenic, meaning it occurs as an unintended consequence of surgery, including spine operations, hernia repairs, hip replacements, pelvic osteotomies, and acetabular fracture repair. Researchers expect the condition to become increasingly common as rates of obesity and diabetes continue to climb worldwide, which makes the search for effective treatments more urgent.

Most patients are managed in outpatient settings, and the first line of attack is deliberately low-tech: lose weight, wear looser clothing, and try physical therapy. Over-the-counter options such as nonsteroidal anti-inflammatory drugs, topical capsaicin, and lidocaine patches come next, followed by prescription anticonvulsants, tricyclic antidepressants, and corticosteroid injections. Alternative approaches, including botulinum toxin injections, acupuncture, and kinesio taping, have shown benefit in small studies. When everything else fails, surgery remains the final option, either cutting the nerve outright in a procedure called neurectomy or freeing it from surrounding tissue in a decompression known as neurolysis. Neither operation is clearly superior to the other, and both carry the risks inherent to any surgery.

Radiofrequency ablation sits in the gap between pills and scalpels. The technique relies on a closed electrical circuit in which high-frequency alternating current flows through an insulated probe tipped with an active electrode. The current causes water molecules near the electrode tip to vibrate rapidly, and in thermal, or conventional, ablation that vibration generates heat, creating a precisely controlled thermal lesion at temperatures of 75 to 90 degrees Celsius sustained for 90 to 180 seconds. The heat produces axonal degeneration and destroys the nerve sheath, interrupting the pain signals traveling to the brain. Two variants exist: cooled ablation, which circulates water to keep the probe itself at around 60 degrees while heating target tissue to 80 degrees and thereby creating a larger lesion, and pulsed ablation, which uses alternating current pulses that allow heat to dissipate between cycles, keeping the electrode tip below 42 degrees and avoiding permanent tissue destruction altogether.

In the new study, a team led by Alaa Abd-Elsayed of the University of Wisconsin School of Medicine and Public Health reviewed the electronic medical records of every patient who underwent thermal radiofrequency ablation of the lateral femoral cutaneous nerve at their center between January 2014 and May 2025. To qualify, patients had to be at least 18 years old, carry a diagnosis of meralgia paresthetica, and have failed conservative management such as transcutaneous electrical nerve stimulation, physical therapy, and massage therapy. Critically, each patient also needed two successful diagnostic nerve blocks with 0.25 percent bupivacaine, each producing at least a 50 percent reduction in pain, before being considered a candidate for ablation. Cooled and pulsed procedures were excluded so the analysis focused purely on the thermal technique.

The procedure itself is performed under ultrasound guidance with the patient lying supine. After the groin is prepped and draped, the nerve is identified at the lateral edge of the sartorius muscle, the overlying skin is anesthetized with lidocaine, and an ablation needle, either 18 or 21 gauge with a 4 or 10 millimeter active tip depending on the provider’s preference, is advanced toward the target. Sensory stimulation is tested to confirm that the needle sits near the nerve, producing tingling in the anterolateral thigh without any motor response, and then two milliliters of 2 percent lidocaine are injected before the lesion is created at 80 degrees Celsius. Patients go home the same day, and none required narcotic pain medication afterward.

The results, though drawn from a small group, are striking. Thirteen procedures across eight patients were analyzed, with two patients undergoing the procedure three times and one twice. The patients averaged just under 50 years of age with a mean body mass index of 35, and six of the eight were women. On the 10-centimeter visual analog scale, average pain scores fell from 5.77 at baseline to 3.23 after the procedure, a statistically significant drop with a p value of 0.007. Nine of the thirteen cases reported a reduction in pain, and among those responders the mean improvement was just over 62 percent. Where duration data were available, relief lasted an average of 6.43 months, with individual responses ranging from 2 to 15 months, and two patients were still pain-free at their most recent clinic visit. Not a single adverse event was recorded.

The findings align with a small but growing literature. Only one prior study has examined thermal ablation of this nerve, reporting roughly 75 percent average pain improvement in six patients, with most still experiencing relief at six months and two of three patients maintaining benefit at one year. A separate study of cooled ablation in seven patients found relief in nine of eleven procedures with nearly 65 percent average improvement lasting just under seven months. Pulsed ablation has been studied more extensively, in six reports covering 21 patients, with pain relief ranging from 75 to 100 percent and symptom recurrence in only one case. Which variant is best remains genuinely unresolved. Pulsed ablation is theoretically safer because it does not create lesions, and some insurers decline to cover it on the grounds that it is still investigational, an irony that highlights how reimbursement policy can lag behind clinical practice. In other pain conditions, however, continuous ablation has generally outperformed pulsed: meta-analyses of lumbar facet joint pain and trigeminal neuralgia, along with randomized trials in knee osteoarthritis and studies of post-herpetic neuralgia, have mostly favored thermal techniques for the magnitude and durability of relief, although results vary by condition.

The authors are candid about the limitations of their work. Because the study was retrospective, follow-up intervals varied and many patients returned only once, restricting the analysis to outcomes within two months of the procedure. The chart review format also prevented the team from capturing variables such as nerve size on ultrasound, and no data on function or quality of life were available, even though these outcomes matter enormously to chronic pain patients. The sample was small, there was no control group, and stratified analyses of factors like needle size, lesion duration, and diabetes were not possible. Still, the complete absence of complications, combined with statistically significant pain reduction and relief lasting on average more than six months, positions thermal radiofrequency ablation as a credible option for patients stranded between failed conservative care and the operating room. The researchers themselves call for prospective studies with larger samples, fixed long-term follow-ups, and additional parameters to identify which patients respond best, a question that will determine whether this technique becomes a standard stopgap or simply another tool in a crowded pain medicine arsenal.

Subject of Research: Thermal radiofrequency ablation of the lateral femoral cutaneous nerve as a treatment for refractory meralgia paresthetica

Article Title: Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series

Article References: Abd-Elsayed, A., Jin, M. Y., Shiferaw, B. T., Murphy, A. P., & Henjum, L. J. (2026). Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series. Advances in Therapy. https://doi.org/10.1007/s12325-026-03819-6

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03819-6

Keywords: meralgia paresthetica, lateral femoral cutaneous nerve, radiofrequency ablation, chronic pain, neuropathic pain, ultrasound guidance, minimally invasive, pain management, peripheral nerve, retrospective case series, obesity, diabetes

The intervention at the heart of the Whole Health Options and Pain Education, or wHOPE, study is the Whole Health Team, an interdisciplinary unit composed of a medical provider, a complementary and integrative health provider, and a health coach. Together, these clinicians provide holistic, non-pharmacological pain care grounded in VA’s broader Whole Health approach, which begins with open-ended inquiry into what matters most to each patient and proceeds through collaborative Personal Health Planning. Over twelve months, patients attended five or more collocated visits with the team’s medical and integrative providers, supplemented by eight or more health coaching visits, while weekly team huddles supported case management and care planning. In a national randomized controlled trial of 764 veterans with moderate to severe chronic pain, the Whole Health Team outperformed both modified Cognitive Behavioral Therapy for Chronic Pain and usual care in reducing pain interference and increasing use of non-pharmacological pain services, with patients also reporting greater improvements in overall health status and treatment satisfaction.

Given that demonstrated effectiveness, the research team led by Natalie Purcell, Liliana C. Moore, William C. Becker, and Karen H. Seal turned to a critical follow-up question: can this model actually be scaled? Because the Whole Health Team approach is not simply multimodal but also team-based, interdisciplinary, and integrated, requiring collocated clinical visits, routine coaching, and weekly huddles, it is more complex and resource-intensive than many other pain interventions. To investigate, the researchers conducted semi-structured interviews with 43 clinicians and staff involved in implementing the intervention, including 14 health coaches, 6 primary care providers, 6 integrative-trained providers, 5 other clinical professionals, 8 local site investigators, and 4 study coordinators. Guided by the Practical Robust Implementation and Sustainability Model, a framework that maps contextual factors from planning through sustainment, the team used template-based rapid analysis to distill themes from interviews lasting 30 to 60 minutes each.

The first major theme concerned team composition and collaboration, and here the clinicians were emphatic. They praised the interdisciplinarity of the model and described working in a genuinely integrated fashion rather than in silos. One medical provider captured the spirit of the collaboration vividly, recalling that the team was working with patients together, talking together, interrupting each other, and asking questions rather than operating separately. Collocated patient visits served as a central venue for this active collaboration, but so did the weekly huddles between visits, where hearing one another’s perspectives helped the team generate multiple options when patients faced challenges. A complementary and integrative health clinician noted that a single lens might not be the best thing for the patient, and expressed appreciation for the ability to hear the same piece of information and encounter completely different perspectives on how to manage it. Clinicians also believed that visible collaboration increased veteran engagement, with one coach observing that simply knowing the team was working together on their behalf gave patients another layer of buy-in.

Consistency of team membership emerged as another essential ingredient. Clinicians stressed that building trust with patients requires time and continuity, and that the twelve-month structure of regular clinical and coaching visits cultivated increased trust, deeper rapport, and genuine continuity of care. Patients came to depend on a familiar team they got to know, which in turn facilitated active involvement in care planning. Yet sustaining that consistency proved difficult. Because clinicians were volunteers lending their time from other duties, they were sometimes pulled off the study to devote resources elsewhere, a problem amplified during the COVID-19 pandemic during which all study interventions were delivered virtually. Clinician turnover interrupted care relationships and left key roles vacant at times, burdening remaining team members and making it harder to practice with a Whole Health approach. Interviewees stressed that team stability must be prioritized if relationship-based care is to survive contact with real-world staffing pressures.

Adequate, formally allocated clinician effort was perhaps the most contested resource of all. The Whole Health Teams operated in an institutional environment focused on optimizing productivity, where bookable hours were measured closely and every clinic scheduling grid was scrutinized. Both clinicians and site investigators emphasized the importance of protected time for team work, including dedicated clinic hours, time for writing notes, and time for the weekly huddles they considered critical. All participating sites did secure protected time, but doing so required staunch advocacy amid competition for clinical resources, and maintaining it remained an ongoing challenge. One site investigator described it as probably the biggest obstacle the team had faced. Clinicians also valued formal orientation to the team, which covered roles, visit protocols, and documentation requirements, though some, including several medical providers, retained uncertainty about their prescribing role relative to patients’ primary care providers, underscoring the need for clearly delineated responsibilities in interdisciplinary teams.

The second major theme involved organizational infrastructure and integration, beginning with the need to fill gaps rather than duplicate existing services. Because some VA health systems already offer pain-management and wellness programs, clinicians and investigators argued that the more resource-intensive Whole Health Team model must demonstrate unique value to make a viable business case for sustainment. They found that value in delivering an integrated, consistent message to each patient. One medical provider lamented that the health system is so fractured that patients see different people who tell them different things, and described the team as an efficient and effective way to help patients with a coherent care plan, noting that veterans like to see that their clinicians are all on the same page. The model also improved the clinicians’ own work experience, fostering mutual support and confidence when caring for patients with complex needs. At the same time, interviewees identified shortcomings: coordination with primary care sometimes felt informal, relying on discretionary co-signature of notes that primary care providers did not always read, and referral pathways to wellness and complementary modalities were often poorly mapped, forcing coaches to act as conduits to information that higher-level staff knew less and less about.

The third theme centered on administration and documentation, an unglamorous but decisive factor. Implementing collocated visits and concurrent health coaching is administratively complicated, and each site benefited from a study-funded, full-time coordinator who scheduled meetings and patients, set up clinic grids, collected point-of-care measures, tracked visits, completed documentation, made reminder calls, and served as an information hub for the whole team. One coordinator cautioned bluntly that if the model were implemented elsewhere, the level of administrative support provided in the study simply would not be available in a clinical service. Clinicians also chafed against standardized clinical note templates designed for study data collection, which felt ill-suited to personalized whole-person care. One provider asked why they needed to do math during a visit and take time away from listening to a veteran’s story, while another complained that templates force a robotic style that annoys patients. The consensus favored simpler, more flexible documentation that could adapt to each visit’s focus.

Perhaps the most striking finding was the depth of clinicians’ belief in the Whole Health model despite every implementation hurdle. Interviewees described practicing in line with their own values, connecting with patients more authentically, and witnessing emotional exit visits in which patients felt deeply cared for and equipped with new resilience and tools. One provider offered a sentiment that captures the model’s philosophy: patients are people, more than just a list of diagnoses, and they are fun and complicated. These accounts align with broader evidence that Whole Health practice may reduce clinician stress and burnout, and with VA survey findings that clinicians engaged in Whole Health view their workplaces more favorably and are less likely to resign. Yet many participants doubted the system would retain and spread the teams, perceiving the model as resource-intensive in an environment that rewards volume and perceived efficiency over quality, experience, and outcomes. They saw the teams as an upstream investment with downstream benefits, but acknowledged that a comprehensive longer-term cost-effectiveness analysis may be needed, particularly as an alternative to interventional pain care.

The study’s lessons amount to a practical blueprint for any health system contemplating integrated, person-centered pain care. Success requires consistent team membership, sufficient protected clinical effort, well-defined roles, team-based training, routine huddles, and skilled administrative support that could be provided by a nurse care manager or medical support assistant in the absence of a study coordinator. It also demands organizational readiness: accessible complementary and integrative health modalities, wellness programs, and health coaching, along with clear referral pathways connecting pain teams to those resources. Deeper integration with primary care, through periodic in-services or coaches already embedded in primary care, could strengthen both patient care and sustainability. As VA continues its transformation into a Whole Health System of Care, and as other integrated systems such as Kaiser Permanente pursue similar holistic models, the wHOPE findings illuminate both the promise and the price of treating chronic pain as a whole-person problem, offering hard-won insight into a care model that the clinicians who delivered it clearly believe is worth sustaining.

Subject of Research: Implementation of interdisciplinary whole-person chronic pain care in the Veterans Affairs Whole Health Team model

Article Title: Implementing Integrated Whole-Person Care for Chronic Pain: Lessons from VA’s Multisite wHOPE Study

Article References: Purcell, N., Moore, L. C., Becker, W. C., & Seal, K. H. (2026). Implementing Integrated Whole-Person Care for Chronic Pain: Lessons from VA’s Multisite wHOPE Study. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10825-5

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10825-5

Keywords: chronic pain, Whole Health, Veterans Affairs, interdisciplinary care, implementation science, complementary and integrative health, health coaching, multimodal care, biopsychosocial, qualitative research, primary care, clinician burnout

The research team, led by Zachary L. Mannes of Columbia University Irving Medical Center and Deborah S. Hasin of Columbia University and the New York State Psychiatric Institute, focused on VHA patients aged 18 to 75 with chronic pain diagnoses. Veterans are a population of particular interest in this debate because chronic pain is among the most common conditions treated in the VA system, and the department has spent more than a decade working to reduce opioid exposure among its enrollees. The VA reports having cut the number of veterans prescribed opioids dramatically since 2012, through initiatives such as the Opioid Safety Initiative and updated clinical practice guidelines that emphasize non-opioid pain management. Against that backdrop, any independent effect of state cannabis policy is difficult to detect, which makes the new study’s methods especially important.

To isolate the effect of legalization from these broader secular trends, the investigators used staggered-adoption difference-in-difference models, a technique that has become the workhorse of modern policy evaluation. Because different states legalized medical cannabis and recreational cannabis at different times, the researchers could compare prescribing outcomes within the same patients and states before and after each law took effect, using states without such laws as the comparison group. States were categorized each year as having no medical or recreational cannabis law, a medical cannabis law only, or both. This approach controls for fixed characteristics of states and for national trends in opioid prescribing, such as the prescribing declines that followed the 2016 CDC opioid guideline, leaving the change associated with legalization itself.

The outcomes the team tracked were carefully chosen to capture different dimensions of opioid risk. They examined whether patients received at least 30 days of prescription opioids, whether they were on long-term opioid therapy, defined as at least 90 consecutive days of opioid supply without a gap of more than 15 days, whether they received high-dose opioids of at least 50 morphine milligram equivalents per day, and whether opioids were co-prescribed with benzodiazepines, a combination strongly linked to overdose death. Each of these measures reflects a distinct clinical decision point, from initiating an opioid prescription to escalating dose or layering on a sedative, and each has been flagged in national guidelines as a marker of potentially hazardous prescribing.

The results paint a nuanced picture. Enactment of a medical cannabis law was associated with a reduction of 0.79 percentage points in the share of patients receiving at least 30 days of opioids, and a reduction of 0.34 percentage points in long-term opioid therapy, relative to states without such laws. Those numbers may sound small, but applied across the enormous VHA population with chronic pain, they translate into thousands of patients shifting away from extended opioid courses. Notably, however, medical cannabis laws were associated with slight increases in the other two risk markers: high-dose opioid prescribing rose by 0.09 percentage points and opioid-benzodiazepine co-prescribing rose by 0.11 percentage points, changes the authors interpret cautiously given their small magnitude.

The story changed when recreational cannabis laws entered the picture. Following the enactment of recreational legalization, on top of existing medical laws, the researchers observed further declines in at least 30-day opioid prescribing, with an additional reduction of 0.14 percentage points, and more substantial drops in the two high-risk markers. High-dose opioid prescribing fell by 0.33 percentage points and opioid-benzodiazepine co-prescribing fell by 0.33 percentage points compared with the period after medical legalization alone. In other words, the transition from medical-only to full legalization was associated not just with less opioid prescribing overall, but with less of the kind of prescribing most closely tied to overdose risk, a pattern that runs counter to fears that wider cannabis availability would compound dangerous drug combinations.

Age emerged as a critical modifier of these effects. The associations between cannabis laws and opioid prescribing were generally more consistent among adults aged 65 to 75, the oldest group in the cohort. This finding is striking given that cannabis use has been rising fastest among older Americans in recent years, and given that older adults face elevated risks from both opioids and benzodiazepines due to altered drug metabolism, falls, and respiratory depression. If legal cannabis access is substituting for opioids anywhere, the data suggest it may be among older veterans with chronic pain, a group in whom clinicians may be particularly motivated to taper high-risk regimens when an alternative becomes legally available.

The authors are careful about what these associations do and do not mean. Difference-in-difference estimates capture population-level changes in prescribing, not individual decisions, and the study cannot confirm that any specific patient replaced an opioid with cannabis. The plausible mechanism, the researchers suggest, involves changes in both patient and clinician treatment decisions: patients in legal states may request cannabis as part of their pain management, and clinicians may feel more comfortable tapering opioids when patients have a sanctioned alternative. Survey evidence has long shown that chronic pain is the leading qualifying condition for medical cannabis licenses, and prior studies in Medicare and Medicaid populations have reported similar directional findings, though the literature overall has been mixed, with some studies finding no effect or effects concentrated in specific subgroups.

The study also arrives amid ongoing scientific uncertainty about whether cannabis actually relieves chronic pain. Randomized trials and meta-analyses of cannabinoids for chronic non-cancer pain have produced modest and inconsistent evidence of benefit, and recent best-practice advice from the American College of Physicians acknowledges both the limited efficacy data and the potential harms of cannabis use. Previous work by some of the same researchers found that cannabis legalization was associated with increases in cannabis use disorder diagnoses among VHA patients with chronic pain, a reminder that expanded access carries its own risks. The new findings therefore do not settle whether cannabis is an effective analgesic; they document a shift in prescribing behavior that accompanies legalization, whatever its underlying cause.

What the study does offer is the most comprehensive picture to date of how cannabis policy intersects with opioid care in the largest integrated health system in the United States. By following VHA patients through a decade in which the legal landscape transformed state by state, and by separating medical from recreational laws and dissecting prescribing into clinically meaningful risk categories, the research moves the debate beyond anecdote. The message for policymakers is measured: greater legal cannabis access appears associated with modest reductions in opioid prescriptions for chronic pain, particularly long-term therapy and, after recreational legalization, high-risk prescribing patterns, while the clinical question of whether cannabis should be recommended for pain remains open. As more states reconsider their cannabis laws, studies like this one will be essential for weighing the trade-offs embedded in those decisions.

Subject of Research: Association between state cannabis legalization and opioid prescribing patterns among veterans with chronic pain

Article Title: Cannabis Legalization and Opioid Prescribing in Veterans Health Administration Patients: 2013–2022

Article References: Mannes, Z. L., Wall, M. M., Stohl, M., Malte, C. A., Olfson, M., Livne, O., Fink, D. S., Simpson, T., Wisell, C. G., Keyhani, S., Martins, S. S., Cerdá, M., Sacco, D. L., Gutkind, S., Maynard, C. C., Sherman, S., Saxon, A. J., & Hasin, D. S. (2026). Cannabis Legalization and Opioid Prescribing in Veterans Health Administration Patients: 2013–2022. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10733-8

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10733-8

Keywords: cannabis legalization, opioid prescribing, chronic pain, Veterans Health Administration, medical cannabis law, recreational cannabis law, long-term opioid therapy, benzodiazepine co-prescribing, difference-in-difference, older adults, pain management, public health policy

The study, led by Benjamin J. Morasco of the VA Portland Health Care System and Oregon Health & Science University, drew its data from the Veterans’ Pain Care Organizational Improvement Comparative Effectiveness study, known as VOICE. That parent trial was a multisite, twelve-month randomized comparative effectiveness trial designed to test two real-world implementations of collaborative care for chronic pain, a model in which primary care teams work with specialized consultants to manage patients’ conditions systematically rather than leaving each clinician to improvise. Participants were randomized to one of two interventions that differed in resource intensity: an intensive interdisciplinary pain team, or a less resource-intensive pharmacist-led collaborative management approach. Both arms were grounded in the same collaborative care architecture, and both were delivered within the routine operations of the Veterans Health Administration, which is precisely what makes the trial pragmatic rather than a test of an idealized clinic that exists only in research settings.

For the secondary analysis, the research team collapsed the two treatment conditions and asked a different question than the original trial: did baseline substance use disorder status predict how patients fared? The answer required first establishing who carried that status. Of the 778 participants enrolled, 250, or 32.1 percent, met criteria for potential substance use disorder at baseline. That figure is striking in its own right, and it aligns with a broader literature documenting that roughly one in three patients on long-term opioid therapy for chronic pain has co-occurring substance use disorder. Epidemiological studies across health systems, including analyses of Norwegian health registries and large electronic health record datasets, have repeatedly found elevated rates of substance use diagnoses among chronic pain patients prescribed opioids, making this population impossible to ignore in any serious effort to improve opioid prescribing.

The demographic and clinical profile of the two groups differed in ways that matter for interpretation. Participants with potential substance use disorder were younger and more likely to have co-occurring mental health diagnoses than participants without it. Yet, critically, the groups showed no differences at baseline in pain interference, pain intensity, or prescription opioid dose. This baseline equivalence is methodologically important: it means that any divergence in outcomes during the trial could plausibly be attributed to substance use disorder status rather than to the groups starting from different levels of pain or different opioid exposures. The researchers measured pain using validated instruments, including the Brief Pain Inventory, which captures both the intensity of pain and the degree to which it interferes with daily functioning, a distinction that has become central to modern pain outcome assessment because interference often responds to treatment even when raw intensity does not fully remit.

The twelve-month results were unambiguous. Participants in both the potential substance use disorder group and the no-disorder group achieved statistically significant reductions in pain interference and pain intensity, alongside reductions in prescription opioid dose. In adjusted analyses that accounted for the demographic and clinical differences between groups, there was no difference between the groups in the magnitude of change on any of these outcomes. In other words, substance use disorder status did not blunt the response to collaborative care, did not prevent opioid dose reduction, and did not leave patients with more residual pain than their peers. For a population often excluded from trials or treated as a special case requiring separate pathways, this is a consequential null finding, in the best sense of the term.

The technical significance of this result becomes clearer when set against the prior evidence base. Earlier randomized trials had tested psychosocial pain interventions specifically tailored to patients in substance use disorder treatment, including work by Ilgen and colleagues and mindfulness-oriented recovery enhancement trials by Garland and colleagues, which showed that dedicated programs could help. But those studies evaluated interventions designed for the substance-using population, leaving open whether mainstream collaborative pain care, the kind most health systems could actually deploy, would work as well for these patients. A prior observational study by Morasco and colleagues had examined pain-related function over twelve months in primary care patients with musculoskeletal pain and found associations worth probing further. The new analysis closes that gap by embedding the substance use disorder question directly inside a rigorous randomized trial of standard collaborative care models, giving the finding a level of causal confidence that observational data cannot provide.

The opioid dose reduction component of the study carries particular weight given the national conversation about tapering. Systematic reviews, including one by Frank and colleagues, have documented that dose reduction and discontinuation of long-term opioid therapy can produce mixed patient outcomes, and observational studies from multiple health systems have linked rapid or forced tapering to overdose, mental health crisis, and other adverse events. The VOICE trial’s collaborative care approach, by contrast, paired dose reduction with active pain treatment, and the new analysis shows that patients with potential substance use disorder achieved dose reductions without differential harm to their pain outcomes. This suggests that the safest tapering is not simply a matter of lowering doses but of lowering them within a supportive treatment structure, and that patients with substance use disorder should not be steered away from such structures on the assumption that they will fail.

Several design features strengthen the study’s real-world relevance. The pragmatic trial design meant that interventions were delivered in ordinary VA primary care settings rather than in specialized research clinics, and the enrollment of 778 patients across multiple sites provided the statistical power to detect meaningful differences if they existed. The identification of potential substance use disorder relied on validated screening approaches, including instruments such as the AUDIT-C for alcohol and the TAPS tool for unhealthy substance use, supplemented by diagnostic codes whose validity in administrative data has been verified through chart review in prior work. The trial was registered at ClinicalTrials.gov as NCT03026790, funded by the Patient-Centered Outcomes Research Institute, and supported by the Department of Veterans Affairs, with the funder having no role in the design, analysis, or decision to publish.

The study’s limitations deserve honest acknowledgment. The population consisted of veterans, most of whom receive integrated care within a single health system, so generalization to civilian populations with fragmented insurance and care remains an empirical question. The substance use disorder classification was based on screening and potential criteria rather than structured clinical interviews, and the analysis examined outcomes at twelve months rather than over longer horizons. The parent trial compared two collaborative care variants and collapsed them for this analysis, so the results speak to collaborative care as a class rather than distinguishing which model works better for which subgroup. Nonetheless, the consistency of the findings across pain interference, pain intensity, and opioid dose outcomes lends credibility to the central conclusion.

The clinical implications are straightforward and potentially practice-changing. Roughly a third of patients on long-term opioid therapy carry a substance use disorder diagnosis, and clinicians have long faced a dilemma: treat the pain aggressively and risk worsening the addiction, or prioritize addiction treatment and leave the pain undertreated. These results suggest that the dilemma is partly false. Collaborative care interventions for chronic pain improved pain outcomes and reduced opioid doses in patients with and without potential substance use disorder alike, indicating that substance use disorder status should not gate access to structured pain treatment. As health systems continue to grapple with the twin burdens of chronic pain and the opioid crisis, the message from this trial is that integrated, team-based care can serve both populations, and that excluding patients with substance use disorder from such care is neither necessary nor supported by the evidence.

Subject of Research: Collaborative care treatment outcomes for chronic pain and opioid dose reduction in patients with and without substance use disorder

Article Title: Pain and Opioid Dose Reduction Based on Substance Use Disorder Status: Secondary Analysis from a Pragmatic Effectiveness Trial

Article References: Morasco, B. J., Hammett, P. J., Krebs, E. E., Seal, K. H., DeRonne, B. M., Lovejoy, T. I., Bohnert, A. S. B., Frank, J. W., Makris, U. E., Naylor, J. C., Painter, J. T., Borsari, B., Hagedorn, H. J., & Becker, W. C. (2026). Pain and Opioid Dose Reduction Based on Substance Use Disorder Status: Secondary Analysis from a Pragmatic Effectiveness Trial. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10816-6

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10816-6

Keywords: substance use disorder, chronic pain, long-term opioid therapy, opioid dose reduction, collaborative care, pragmatic trial, veterans health, pain interference, pain intensity, primary care, comparative effectiveness, opioid prescribing

Sensory gating is one of the nervous system’s most economical tricks. When two identical stimuli arrive in quick succession, the brain’s response to the second is normally dampened relative to the first, a phenomenon measured by the ratio of the second response to the first. This suppression is not fixed; it depends heavily on the interstimulus interval, the gap between the two pulses. At very short intervals the cortical circuitry is still recovering and the second response is strongly attenuated, while at longer intervals the response gradually rebounds. The pattern reflects the recovery dynamics of thalamocortical synapses and local inhibitory circuits, and it allows the cortex to emphasize novel input while suppressing redundant input. In clinical settings, disturbances of sensory gating have been linked to a range of conditions, from migraine to schizophrenia, making the mechanism a sensitive readout of brain health.

To test how sustained pain reshapes this system, the team applied paired-pulse electrical stimulation to the median nerve of anesthetized rats, delivering two pulses separated by interstimulus intervals of 35, 50, 80, 140, and 500 milliseconds. Evoked potentials were recorded directly from the primary somatosensory cortex, the cortical region that receives and processes touch and proprioceptive information from the body. The researchers then injected capsaicin, the pungent compound in chili peppers that activates TRPV1 receptors on nociceptive C-fibers, into the territory served by the nerve. Capsaicin produces a well-characterized model of sustained peripheral nociceptive input: it does not destroy the nerve, but it drives a prolonged barrage of pain-related signals from the periphery into the central nervous system. Recordings were repeated at 60 and 120 minutes after the injection, allowing the team to track how the cortical response evolved as the pain signal persisted.

The results were striking in their asymmetry. Compared with vehicle-treated controls, capsaicin significantly increased the amplitude and the area under the curve of the first response, S1, while simultaneously decreasing the S2/S1 amplitude ratio across the entire two-hour recording window. In other words, the cortex responded more vigorously to the initial stimulus, but the relative suppression of the second stimulus deepened. At first glance that combination may seem paradoxical, but the authors interpret it as a change in response gain: the whole input-output function of the cortical circuit was scaled up, so the first response grew while the recovery-dependent second response failed to keep pace. Crucially, this effect appeared to be independent of the interstimulus interval. In the normal brain, the degree of gating varies systematically with the gap between pulses; after capsaicin, that orderly interval-dependent structure was largely lost, replaced by a flattened, interval-insensitive profile.

The study went beyond conventional evoked potentials by examining high-frequency oscillations, or HFOs, the fast rhythmic components superimposed on somatosensory evoked responses. These oscillations are thought to arise from distinct neuronal generators, with early components reflecting activity in inhibitory interneuron networks and later components tied to thalamocortical relay activity. When the researchers decomposed the evoked responses into frequency bands, they found that both the early and late components of the S1 response were significantly increased in the 50 to 150 Hz domain after capsaicin. Even more notably, the early component of the area under the S1 response increased prominently in the 400 to 800 Hz band, an extremely fast range that is rarely accessible in routine human recordings but can be resolved with direct cortical electrodes in animal models.

These frequency-specific changes carry physiological weight. The 50 to 150 Hz range overlaps with gamma-band activity, which is associated with local cortical processing and has been implicated in pain-related cortical dynamics in both animal and human studies. The 400 to 800 Hz bursts, sometimes called very high-frequency oscillations, are believed to index the firing of populations of inhibitory interneurons in the superficial layers of the cortex. A disproportionate amplification of the early, very high-frequency component of S1 suggests that sustained nociceptive input acts at the earliest stages of cortical sensory processing, altering the excitability of the local inhibitory network before the signal is even relayed through the canonical cortical columns. The authors propose that capsaicin-induced nociceptive drive modified the response gain of the cortex while simultaneously abolishing the normal interval-dependent recovery function, a dual insult that degrades the brain’s ability to temporally parse incoming sensory information.

Why does this matter for understanding chronic pain? Temporal discrimination, the ability to distinguish two stimuli that arrive close together in time, depends on precisely the gating mechanism the study measured. Patients with neuropathic pain and other chronic pain conditions frequently report allodynia, hyperalgesia, and difficulty separating simultaneous sensations, symptoms that could plausibly arise from a cortex whose gain has been turned up and whose interval-dependent filter has been disabled. The current findings provide an electrophysiological substrate for those clinical observations: sustained peripheral nociceptive input does not merely add a painful signal on top of normal processing, it reorganizes the processing itself. The disproportionate effect on S1, the initial cortical response, points to early sensory processing as a key site of pain-related plasticity, rather than the higher-order associative regions that have traditionally attracted most attention.

The methodology deserves attention as well. By sampling five interstimulus intervals spanning more than a fourteenfold range, from 35 to 500 milliseconds, and by recording at two time points after the nociceptive challenge, the experiment captured both the temporal structure and the time course of the gating disruption. The finding that capsaicin’s effects did not vary meaningfully with interval values was itself an important negative result: the authors state that they could not clearly detect a significant contribution of ISI values to capsaicin’s effects on sensory processing regulation. That absence of interval dependence is precisely what one would expect if sustained nociceptive input had overwritten the recovery dynamics of the thalamocortical circuit, replacing a tuned filter with a uniformly amplified, uniformly suppressed regime.

There are, of course, limits to what an anesthetized rat model can tell us about human pain perception. Capsaicin injection is an acute model of sustained nociception rather than a true chronic pain state, and cortical responses recorded under anesthesia may differ in important ways from those in a behaving, conscious animal. The authors also note that the study was conducted without external funding, and the work was approved by the Gazi University Local Ethics Committee for Animal Experiments. Nevertheless, the model has strong translational precedent, and the electrophysiological markers identified here, particularly the S2/S1 ratio and the high-frequency oscillation profile, have direct analogues in human somatosensory evoked potential recordings, raising the possibility of biomarkers for pain-related cortical dysfunction.

The broader lesson is that pain is not just a sensation; it is a modulator of sensation. By driving a sustained stream of nociceptive traffic into the thalamocortical system, a persistent pain source appears to hijack the gain control and temporal filtering that the cortex relies on to organize all incoming sensory information. If confirmed in further studies, this mechanism could help explain the sensory chaos that many chronic pain patients describe, and it suggests that therapies aimed at restoring normal cortical gating, rather than simply blocking pain signals at their source, might offer a route to relieving the full burden of the condition. For now, the rat cortex has delivered a clear message: when pain will not stop talking, the brain stops listening properly to everything else.

Subject of Research: Effects of sustained peripheral nociceptive input on sensory gating in the rat primary somatosensory cortex

Article Title: Sustained peripheral nociceptive input disrupts interstimulus-interval-dependent sensory gating in the rat primary somatosensory cortex

Article References: Tepe, N., Boran, H. E., Geduk, S., Dileköz, E., Sara, Y., & Bolay, H. (2026). Sustained peripheral nociceptive input disrupts interstimulus-interval-dependent sensory gating in the rat primary somatosensory cortex. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01053-y

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01053-y

Keywords: sensory gating, chronic pain, capsaicin, somatosensory cortex, high-frequency oscillations, interstimulus interval, nociception, thalamocortical pathway, evoked potentials, neurophysiology, TRPV1, BMC Neuroscience

The study enrolled 150 patients with chronic non-cancer pain, all attending the pain clinic of a tertiary military hospital. Researchers divided participants into two groups based on their self-reported pain intensity on the widely used Numerical Rating Scale, or NRS. Patients scoring 5 or below were classified as having mild-to-moderate pain, while those scoring above 5 fell into the severe pain category. This simple cutoff allowed the team to compare psychological outcomes across a clinically meaningful threshold, since a score above 5 on the eleven-point scale is generally considered the point at which pain begins to interfere substantially with daily functioning.

To assess mental health, the investigators used two of the most established clinician-rated instruments in psychiatry: the Hamilton Anxiety Rating Scale, known as HAM-A, and the Hamilton Depression Rating Scale, in its seventeen-item version, HAM-D-17. Clinically significant anxiety was defined as a HAM-A score of 14 or higher, while clinically significant depressive symptoms were defined as a HAM-D-17 score of 17 or higher. Patients meeting either threshold were counted as having clinically significant anxiety and/or depressive symptoms. Quality of life was measured with the Short Form-36 Health Survey, a generic instrument that captures physical, social, and emotional dimensions of wellbeing.

The differences between the two pain groups were striking. Patients with severe pain had a mean anxiety score of 19.2, compared with 9.8 in the mild-to-moderate group, a difference that was highly statistically significant. Depression scores followed the same pattern, averaging 21.3 in the severe pain group versus 11.5 among those with milder pain. Both comparisons yielded P values below 0.001, indicating that the likelihood of seeing such large gaps by chance alone is vanishingly small. In practical terms, the average severe pain patient scored well above the clinical thresholds for both conditions, while the average mild-to-moderate patient scored well below them.

Those score differences translated into a dramatic gap in the proportion of patients crossing the clinical line. Fully 80 percent of patients with severe pain met criteria for clinically significant anxiety and/or depressive symptoms, compared with just 35.7 percent of those with mild-to-moderate pain, again a difference with a P value below 0.001. Quality of life told a matching story: the severe pain group averaged 48.2 on the Short Form-36, against 68.4 for the milder pain group. Taken together, the data sketch a picture in which pain intensity, psychological distress, and life quality move together in a tightly coupled system.

To determine whether severe pain was independently associated with psychological symptom burden, the researchers turned to binary logistic regression, a statistical technique that estimates the odds of an outcome while adjusting for other contributing factors. In multivariable models that accounted for severe pain, age of 50 years or older, pain duration of 12 months or longer, sleep disturbance, sex, and marital status, several factors emerged as significant. Severe pain itself carried an adjusted odds ratio of 7.89, meaning that patients with severe pain had nearly eight times the odds of clinically significant anxiety and/or depressive symptoms compared with those whose pain was milder, with a P value below 0.001.

The other independent contributors were more modest but still meaningful. Patients aged 50 or older had 2.20 times the adjusted odds of significant symptoms, a finding that reached statistical significance at P equal to 0.048. Pain that had persisted for 12 months or longer was associated with an adjusted odds ratio of 2.41, significant at P equal to 0.029. Sleep disturbance, a complaint that is nearly ubiquitous in chronic pain populations, independently raised the odds by a factor of 3.15, with a P value of 0.005. The fact that sleep disturbance remained significant after adjustment suggests that disrupted sleep is not merely a byproduct of pain intensity but a distinct thread in the web linking physical suffering to emotional collapse.

The biological plausibility of these connections is well supported by prior research. Chronic pain, anxiety, depression, and sleep disruption share overlapping neural circuitry, including limbic regions that govern emotion and descending pathways that modulate pain perception. Persistent nociceptive input can sensitize central pain pathways, while sleep loss amplifies pain sensitivity and impairs emotional regulation, creating a self-reinforcing loop in which each factor worsens the others. The new study does not untangle the direction of these relationships, but its adjusted odds ratios quantify how strongly the components of this loop cluster together in a real-world clinical population.

The authors are careful about the limits of their design. Because the study is cross-sectional, capturing a single snapshot in time, causal inferences cannot be drawn; it is impossible to say whether severe pain drives anxiety and depression, whether psychological distress amplifies pain perception, or whether both arise from shared underlying mechanisms. In addition, the researchers relied on symptom severity scales rather than structured diagnostic interviews, so formal psychiatric diagnoses cannot be confirmed. The military hospital setting also means the findings describe a specific patient population, and generalization to other contexts should be made cautiously. These caveats do not diminish the clinical signal, but they frame it as association rather than causation.

Even so, the practical implications are clear. The authors conclude that routine screening for anxiety and depressive symptoms is essential for older patients with prolonged, severe pain, so that integrated management addressing both physical and psychological dimensions of suffering can begin early. With roughly four in five severe pain patients in this cohort showing clinically significant psychological symptom burden, treating pain alone may leave the most disabling part of the illness untouched. For pain clinics, the message is that a Numerical Rating Scale score above 5 should trigger not just an analgesic review but a mental health assessment, and that asking about sleep may be one of the simplest and most informative questions a clinician can pose.

Subject of Research: The association between severe chronic pain, anxiety and depressive symptoms, and sleep disturbance in Pakistani patients

Article Title: Severe chronic pain is associated with higher anxiety and depressive symptom burden and sleep disturbance in Pakistani patients

Article References: Jalal, O., Jaffar, S., Kundi, F. K., Khaliq, S., Mufti, A. A., Chaudhry, Z. A., Ahmad, S. I., Khan, S., Anees, S., & Dalil, L. (2026). Severe chronic pain is associated with higher anxiety and depressive symptom burden and sleep disturbance in Pakistani patients. Discover Psychology. https://doi.org/10.1007/s44202-026-00882-6

Image Credits: AI Generated

DOI: 10.1007/s44202-026-00882-6

Keywords: chronic pain, anxiety, depression, sleep disturbance, quality of life, pain severity, Hamilton rating scales, military population, Pakistan, cross-sectional study, mental health screening, pain clinic

The research team, led by Chen Zarecki of Ariel University and the Max Stern Yezreel Valley College with colleagues including Carmit Satran, Anis Kaldawy, Riki Tesler, and Shiran Bord, set out to address a gap that has persisted in the endometriosis literature. The condition has been studied extensively from a biomedical perspective, focusing on lesions, hormones, and surgical outcomes, but its cultural and ethnic dimensions have received far less attention. The authors emphasize that their goal was not to produce nationally representative prevalence estimates. Rather, they wanted to examine associations and differences in what they call Perceived Life Course Impact, or PLCI, and in social support among women diagnosed with endometriosis across ethnic groups.

The study recruited 535 Jewish women and 212 Arab women through an online panel rather than a clinical setting. Within each group, researchers compared women with a confirmed endometriosis diagnosis to matched controls: 267 Jewish women with endometriosis against 268 without, and 58 Arab women with the condition against 154 without. Participants completed validated questionnaires assessing PLCI across three life domains, namely intimate relationships, education, and employment, along with measures of social support, social negativity, perceived mental health, and pain. The design was cross-sectional, meaning it captured a snapshot in time rather than following women over years, and the researchers used analyses of covariance and hierarchical regression models to probe ethnic and diagnostic differences while controlling for demographic and health-related covariates.

The first and most striking result is how consistently endometriosis disrupted lives regardless of ethnicity. Women with the disease, whether Jewish or Arab, reported significantly higher perceived life course impact in every domain measured, poorer mental health, lower social support, and higher social negativity compared with women without the diagnosis. The statistical strength of these differences, reported at p < .001, indicates that the associations are unlikely to be artifacts of sampling variation. In other words, the burden of endometriosis on intimate relationships, educational attainment, and employment was substantial across the board, confirming that this is not merely a condition of cyclical pain but one that reshapes the trajectory of a woman’s adult life.

Yet the study also revealed meaningful cultural patterning within that shared burden. Arab women reported higher PLCI regarding education than Jewish women, suggesting that the disease may interfere more heavily with schooling and academic progression in that community. Jewish women, by contrast, reported better social interaction patterns than their Arab counterparts, hinting at differences in how openly the illness can be discussed or how readily social networks absorb its disruptions. Perhaps most unexpectedly, Jewish women with endometriosis reported worse mental health and higher pain levels than Arab women with the same diagnosis, a finding that complicates any simple assumption that minority status automatically translates into worse outcomes on every measure.

These divergences point toward what the researchers describe as cultural pathways to health inequity. The ways a chronic, stigmatized, and often invisible illness is experienced and interpreted are shaped by ethnicity, culture, and social environment, the authors conclude. In communities where menstrual pain is surrounded by silence or taboo, women may delay disclosure, normalize severe symptoms, or encounter less empathy from family and employers. In settings where discussion is more open, the emotional weight of the disease may surface more readily, which could partly explain the higher reported mental health burden among Jewish women in the sample. The study’s design cannot disentangle all of these mechanisms, but the patterns it documents are consistent with the idea that illness is lived through culture as much as through tissue.

The regression models added a second layer of insight by identifying which social factors best predicted the perceived life course impact. For the whole sample, social negativity, essentially the experience of criticism, dismissal, or hostility from one’s social surroundings, emerged as the strongest social predictor of PLCI, with social support and menstrual pain joining it for the most part. This hierarchy held even among women with endometriosis specifically: social negativity remained the strongest predictor, accompanied by social support, menstrual pain, and, notably, driving time to the health care clinic. The appearance of travel distance as a significant predictor is a reminder that access to care is not only about insurance or availability of specialists but about the literal geography between a woman in pain and the help she needs.

That social negativity outweighed even pain severity as a predictor of life disruption is arguably the study’s most provocative implication. It suggests that the reactions of partners, families, employers, and communities may do as much damage as the disease itself, amplifying the consequences of symptoms into lost education, stalled careers, and strained relationships. For clinicians, this reframes endometriosis management: treating lesions and prescribing hormonal therapy may be necessary but insufficient if patients return to environments that minimize or stigmatize their suffering. The authors argue that their findings highlight the need for culturally sensitive interventions that address both clinical symptoms and the social and cultural determinants of health.

The study carries methodological caveats worth noting. Its cross-sectional design cannot establish causality, so it remains possible, for example, that women whose lives have been more disrupted perceive more social negativity rather than the reverse. The online panel recruitment and the modest number of Arab women with endometriosis, 58 in total, limit generalizability, and the authors explicitly caution against reading their figures as prevalence estimates. Self-reported measures of perceived impact and mental health are also subjective by nature, even when drawn from validated instruments. Still, the consistency of the diagnostic differences across two ethnically distinct populations, and the persistence of social negativity as the dominant predictor in multiple models, lends weight to the central claim that social context is a genuine determinant of endometriosis outcomes.

Globally, endometriosis affects an estimated one in ten women of reproductive age, and average diagnostic delays of years remain the norm in many health systems. Studies like this one push the conversation beyond the examination room, arguing that inequity in women’s health is produced not only by biology and access to surgery but by the cultural scripts that determine whose pain is believed, whose symptoms are discussed, and whose life plans are allowed to bend around a chronic illness. For the Jewish and Arab women in this study, the diagnosis was a shared experience; the meaning of that experience, and its reach into education, work, and intimacy, was anything but uniform. Closing that gap, the researchers suggest, will require health systems that treat culture not as background noise but as a clinical variable in its own right.

Subject of Research: Cultural and ethnic differences in the perceived life course impact of endometriosis among Jewish and Arab women in Israel

Article Title: Cultural pathways to health inequity: perceived life course impact of endometriosis among Jewish and Arab women in Israel

Article References: Zarecki, C., Satran, C., Kaldawy, A., Tesler, R., & Bord, S. (2026). Cultural pathways to health inequity: perceived life course impact of endometriosis among Jewish and Arab women in Israel. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03038-z

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03038-z

Keywords: endometriosis, health equity, ethnicity, women's health, social support, social negativity, mental health, perceived life course impact, Israel, cross-sectional study, culturally sensitive care, chronic pain

The core problem with conventional peripheral nerve stimulation lies in its lack of selectivity. When a cuff electrode wrapped around a nerve delivers current, it activates many types of fibers at once: the large, heavily myelinated Aα and Aβ fibers that carry touch and proprioceptive signals toward the spinal cord, the thinner Aδ fibers associated with sharp pain, and the efferent motor fibers that drive muscles. For pain relief, clinicians generally want to activate only the large sensory Aα/Aβ fibers, which can suppress pain transmission through gating mechanisms in the spinal cord. But because electrical stimulation cannot reliably distinguish afferent sensory fibers from efferent motor fibers, the current must be capped at levels that avoid unwanted muscle contractions. That ceiling can leave the therapeutic target population under-activated, blunting the treatment’s analgesic effect.

Optogenetics has long been proposed as an elegant solution. By introducing light-sensitive proteins such as channelrhodopsin 2 (ChR2) into specific populations of neurons, researchers can activate precisely those cells with pulses of light while leaving neighboring fibers untouched. In the new study, the team used transgenic mice expressing ChR2 and recorded compound action potentials (CAPs), the summed electrical signature of many axons firing together, from the sciatic nerve of anaesthetized animals. The results confirmed the selectivity promise: optogenetic stimulation activated Aα/Aβ fibers with impressive precision and produced no motor response at all, something electrical stimulation cannot achieve. For a field struggling to silence pain without triggering twitching limbs or tingling side effects, that selectivity is a major prize.

But there was a catch, and it is a serious one. When the researchers delivered tonic optogenetic stimulation, continuous trains of light pulses lasting up to 60 seconds at clinically relevant frequencies ranging from 4 to 100 Hz, the nerve responses faded dramatically. The optically evoked compound action potentials, or oCAPs, declined in an exponential and strongly frequency-dependent manner, with the statistical analysis showing a highly significant frequency effect (p < 0.001). At stimulation rates above 20 Hz, the response often vanished entirely, leaving no detectable signal even while the light continued to flash. In other words, the very thing that makes optogenetics selective also makes it fragile: the light-activated channels and the fibers themselves fatigue quickly, and the technique as it currently stands is simply untenable for the sustained stimulation that real-world pain therapy demands, even at low frequencies.

Electrical stimulation did not escape unscathed either. The electrically evoked compound action potentials, or eCAPs, also declined over the course of the 60-second stimulation trains, and they did so in a frequency-dependent, dual-phase exponential pattern that the team captured statistically (p < 0.001). This biphasic decay suggests two overlapping processes: a rapid initial drop, likely reflecting activity-dependent changes in axonal excitability such as hyperpolarization or potassium accumulation, followed by a slower secondary decline. Clinicians and device engineers have long observed that nerve responses wane during continuous stimulation, and this study quantifies that phenomenon precisely in the large sensory fiber population that pain therapy seeks to recruit, across the exact frequency range used in clinical peripheral nerve stimulation devices.

The most striking findings emerged when the researchers combined the two modalities. Delivering light and electrical stimulation together produced what the team describes as a facilitated response: the combined electrically and optically evoked CAP, or cCAP, was larger than what either stimulus could achieve alone. Across the entire stimulation period, more than 85 percent of the recorded responses showed this facilitation, and critically, the effect was maintained regardless of stimulation frequency (p = 0.33). The rapid initial reduction in response amplitude for combined stimulation was actually greater than that seen with electrical stimulation alone (p < 0.05), but after that fast phase, the response settled into a similar secondary decline as the electrical-only condition (p = 0.10). The net result, however, was a response that stayed larger and more sustained than either modality could deliver on its own.

Why does combining light and electricity boost the response? The mechanistic picture that emerges from this and earlier work is that the two stimuli act on the fibers through partially independent pathways. Electrical stimulation directly depolarizes the axonal membrane at the electrode, while optogenetic stimulation opens light-gated channels distributed along the ChR2-expressing sensory neurons. When both are applied, the depolarizations summate, preferentially boosting activation in the genetically targeted population of large sensory fibers. Because the electrical component does not fatigue in the same way as the optical one, it appears to prop up the response during the periods when the optically driven component would otherwise collapse. The consequence is a stimulus that retains the selectivity of the optogenetic approach, targeting only the Aα/Aβ fibers, while achieving the sustained responsiveness that pure light-based stimulation lacks.

The clinical implications are considerable. Peripheral nerve stimulation devices are already implanted in patients for chronic pain, but their efficacy is limited by the current ceilings imposed by motor fiber activation and by the inherent non-selectivity of electrical currents. If a hybrid device could deliver a small, safe electrical pulse alongside targeted optical activation of ChR2-expressing sensory fibers, it might achieve stronger and more sustained recruitment of the therapeutic fiber population without crossing into motor territory. The Melbourne team’s demonstration that facilitated responses persist across the full 4 to 100 Hz clinical frequency range, and throughout stimulation trains lasting a full minute, provides exactly the kind of preclinical evidence needed to justify pushing this approach toward translational development. This study adds to growing evidence that combined stimulation could improve the analgesic effect of existing peripheral nerve stimulation methods.

Significant hurdles remain before any such device reaches patients. Optogenetics in humans requires gene delivery, typically via adeno-associated viruses, to introduce light-sensitive proteins into the target neurons, and translating the transgenic mouse approach used here into a safe and durable human therapy is a formidable challenge involving dosing, immune responses and long-term expression. Light delivery to deep peripheral nerves also requires implanted LEDs or optical fibers, adding engineering complexity. The study itself was conducted in isoflurane-anaesthetized mice over relatively short stimulation windows, so questions about responses over hours, days or weeks of continuous use remain open. Ethical oversight was rigorous: all procedures were approved by the St Vincent’s Hospital Animal Ethics Committee in Melbourne and conducted under Australian animal welfare guidelines.

Nevertheless, the study represents a methodical and important step forward. By systematically comparing electrical, optogenetic and combined stimulation across clinically relevant frequencies and durations, and by quantifying the decay dynamics of each with rigorous statistical modeling, Ardren, Wrobel, Matarazzo, Thompson, Fallon, Richardson and their colleagues have given the neuromodulation field a clear-eyed assessment of what each approach can and cannot do. Optogenetics alone, however selective, cannot yet sustain the signals needed for therapy. Electrical stimulation alone, however durable, cannot select its targets. Together, the data suggest, they cover each other’s weaknesses. For the millions of chronic pain patients whose conditions resist every existing treatment, that combination, light and current working in concert, may be the most promising avenue yet for making nerve stimulation devices finally live up to their promise. The research was funded by the National Health and Medical Research Council and the Bionics Institute Incubation Fund, with support from the Victorian Government, and is published open access so that researchers worldwide can build on its findings immediately.

Subject of Research: How optogenetic, electrical and combined stimulation recruit large sensory nerve fibers in the mouse sciatic nerve during sustained neuromodulation for chronic pain treatment.

Article Title: Recruitment of Aα/Aβ fibers during tonic electrical, optogenetic and combined stimulation in the mouse sciatic nerve

Article References: Ardren, M. G., Wrobel, B., Matarazzo, J. V., Thompson, A. C., Fallon, J. B., & Richardson, R. T. (2026). Recruitment of Aα/Aβ fibers during tonic electrical, optogenetic and combined stimulation in the mouse sciatic nerve. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01049-8

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01049-8

Keywords: optogenetics, peripheral nerve stimulation, chronic pain, neuromodulation, sciatic nerve, A-alpha/A-beta fibers, compound action potential, channelrhodopsin, electrical stimulation, neuroengineering, BMC Neuroscience, pain therapy

Group medical visits, sometimes called shared medical appointments, bring together multiple patients who live with the same condition to receive clinical care, health education, and peer support in a single session. The model has gained traction in primary care settings as a way of extending scarce clinician time while addressing the psychological and social dimensions of illness that individual visits often leave untouched. For chronic pain, the promise is especially significant, because isolation and stigma can intensify pain perception and deepen disability. Patients with conditions such as fibromyalgia, chronic back pain, and persistent joint pain frequently report feeling dismissed or disbelieved, and that sense of invalidation can erode both mental health and engagement with care. The study set out to understand, in detail, exactly how a group format counters those forces.

The research was conducted within a randomized trial based at safety-net clinics in San Francisco, which serve patients regardless of their ability to pay. Safety-net populations carry a disproportionately heavy burden of chronic pain, along with the social stressors, limited access to specialists, and economic precarity that make multimodal treatment difficult to deliver. The intervention evaluated in the trial consisted of twelve weekly sessions, each lasting two hours, that combined clinical care with structured pain education, mindfulness practice, gentle movement, and group discussion. Rather than being led by a single provider, the sessions were co-facilitated by a team that included primary care and behavioral health clinicians alongside a movement and mindfulness instructor, an arrangement designed to reflect the biopsychosocial nature of chronic pain itself.

The research team, led by corresponding author Maria T. Chao of the Osher Center for Integrative Health and the Department of Medicine at UCSF, collected qualitative data from participants in the trial to map the social dynamics that unfolded inside the groups. Their analysis was organized around a well-established framework in social science that distinguishes four types of social support: emotional, appraisal, informational, and instrumental. Emotional support refers to empathy, warmth, and a sense of being cared for. Appraisal support involves honest feedback that helps a person evaluate their own situation and coping efforts. Informational support is the exchange of practical knowledge and advice, while instrumental support is tangible assistance, such as goods or services. The qualitative findings showed that all four types emerged robustly within the group visit setting, and that each reinforced the others.

Emotional support was anchored in what participants described as a nonjudgmental space built on trust. In conventional clinical encounters, patients with chronic pain often feel pressure to perform wellness or apologize for their limitations. Within the groups, that pressure visibly dissolved. Participants reported, for example, that arriving late or missing a session was met not with reproach but with understanding, which removed a layer of shame that can otherwise drive people away from treatment altogether. The trust also allowed patients to name and discuss grief, an emotion that chronic pain researchers have long identified as central to the experience of losing function, identity, and future plans. Being able to voice that grief among peers who genuinely understood it transformed the group from a medical appointment into a community of recognition.

Appraisal support flowed in part from the facilitators themselves. In a striking reversal of the traditional clinical hierarchy, facilitators disclosed their own setbacks and struggles, modeling honest self-assessment and showing participants that difficulty is part of every coping journey rather than a sign of failure. Peers then amplified this effect by offering affirmations that encouraged self-compassion, gently challenging the harsh self-judgment that so often accompanies chronic illness. This kind of feedback is delicate work; too much criticism can wound, and too much reassurance can ring hollow. The study suggests that the combination of credible facilitator disclosure and peer affirmation created a calibrated environment in which patients could reevaluate their progress without feeling judged, an effect that is difficult to reproduce in a fifteen-minute individual visit.

Informational support emerged from two complementary channels. The first was the formal curriculum, which delivered structured pain education, mindfulness training, and movement instruction in a way that patients could absorb gradually over twelve weeks. The second, and perhaps more distinctive, was the informal exchange among peers, who traded practical tips born of lived experience. One example highlighted in the study was the suggestion to use frozen water bottles as an inexpensive aid for plantar fasciitis, a simple hack that no clinician had mentioned but that a fellow patient had discovered and tested. These exchanges transform patients from passive recipients of expert knowledge into contributors, and the credibility of advice from someone who shares the same condition can make it more persuasive than equivalent information delivered from a position of authority.

Instrumental support, the most tangible of the four types, also flourished. Peers brought food to share, a small gesture with outsized social meaning, signaling care and mutuality across the group. Facilitators, meanwhile, used their clinical roles to connect participants with additional services, referring them for counseling and other forms of care that addressed needs beyond what the group sessions themselves could provide. In this way, the group visit functioned not only as a therapeutic space but as a conduit into the broader health system, helping safety-net patients navigate resources that often remain fragmented and hard to reach. The interplay was mutual: emotional safety made information sharing possible, and shared practical help deepened emotional bonds.

The study’s authors frame these findings through the lens of the biopsychosocial model of chronic pain, which holds that pain is produced and sustained by an interaction of biological, psychological, and social factors, and that effective treatment must therefore address all three. Group medical visits, they argue, are one model of biopsychosocial chronic pain management in primary care, and the four forms of social support they mobilize should be understood as core therapeutic processes rather than pleasant side effects. Through deliberate facilitation and structured peer exchange, the group format activates mechanisms, reduced stigma, honest appraisal, practical knowledge, and tangible aid, that are otherwise scattered or absent from conventional care. The implications for a health system confronting a national chronic pain epidemic and a shortage of pain specialists are considerable, pointing toward a scalable, humane, and evidence-informed way to deliver whole-person care where it is needed most.

Subject of Research: Social support mechanisms in group medical visits for chronic pain management in primary care

Article Title: Patients with chronic pain may benefit from group medical visits

Article References: Patients with chronic pain may benefit from group medical visits. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: chronic pain, group medical visits, primary care, social support, biopsychosocial model, integrative health, mindfulness, peer support, safety-net clinics, pain education, self-compassion, Annals of Family Medicine